Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alaunos Therapeutics, Inc. (TCRT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.9261-0.0055 (-0.59%)
At close: 01:00PM EST
0.9500 +0.02 (+2.58%)
After hours: 03:31PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

    Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON)Actively enrolling patients in TCR-T Library Phase 1/2 trial at the second dose level; expect to treat next patient in 4Q22Expanded manufacturing capacity to produce two products simultaneouslyExpect to file Investigational New Drug (IND) amendment in 4Q22 to add two additi

  • GlobeNewswire

    Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

    HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results. Register for the live webcast using the link here or by visit

  • GlobeNewswire

    Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

    Data supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Company’s hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Company’s human neoantigen T-cell

Advertisement
Advertisement